Aktienanalyse zu Tenaya Therapeutics Inc (TNYA)

KI-Analyse of Tenaya Therapeutics Inc (TNYA)

Verkaufen

Tenaya Therapeutics Inc is not a good buy right now. The stock is currently trading at $0.361, which is very close to its 52-week low of $0.36. The RSI is at a low 23.328, indicating that the stock is oversold, but this could also suggest a continued downward trend. Additionally, the company has reported significant losses, with a net income loss of $43,393,000 in Q2 2026, and a gross margin of only 100% in the most recent quarters, which is not sustainable. The stock has declined 73.84% over the past year, and insider selling has increased by 55,373.56% in the last month, indicating a lack of confidence from those within the company. The main risk is the company's ongoing financial losses and the potential for further declines in stock price.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Tenaya Therapeutics Inc (TNYA) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -2.21.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

-2.21

Aktuelles P/E

0.00

Überbewertet

-0.79

Unterbewertet

-3.63

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

-1.15

Aktuelles EV/EBITDA

-0.49

Überbewertet

0.41

Unterbewertet

-2.70

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

65.91

Aktuelles P/S

33.72

Überbewertet

203.26

Unterbewertet

-71.43

Alphio-AI-Kursszenarien für TNYA

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%TNYA

$1.05

Szenariopreis

B

Basis

Basis · 50%TNYA

$0.92

Szenariopreis

B

Bärisch

Bärisch · 25%TNYA

$0.82

Szenariopreis

Whales, die TNYA halten

C

Casdin Capital, LLC

+ HältTNYA

+3.80%

3-Monats-Rendite

S

StepStone Group Inc.

+ HältTNYA

-0.27%

3-Monats-Rendite

TNYA FAQ – beantwortet von Alphio AI

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Tenaya Therapeutics Inc is not a good buy right now. The stock is currently trading at $0.361, which is very close to its 52-week low of $0.36. The RSI is at a low 23.328, indicating that the stock is oversold, but this could also suggest a continued downward trend. Additionally, the company has reported significant losses, with a net income loss of $43,393,000 in Q2 2026, and a gross margin of only 100% in the most recent quarters, which is not sustainable. The stock has declined 73.84% over the past year, and insider selling has increased by 55,373.56% in the last month, indicating a lack of confidence from those within the company. The main risk is the company's ongoing financial losses and the potential for further declines in stock price.